Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Three Low-Priced Stocks With Explosive Growth Potential
When investors hear the term “cheap stocks,” many immediately picture high-risk speculation and questionable schemes. Yet the reality is more nuanced. Selecting undervalued companies strategically can unlock significant opportunities without excessive volatility. The key distinction is this: not all inexpensive stocks are created equal. Established corporations trading at depressed valuations offer different characteristics than speculative ventures. More importantly, even newer publicly traded companies can demonstrate genuine merit if you dig beyond surface-level metrics. For investors willing to examine smaller-cap opportunities with real fundamentals, here are three compelling low-priced stocks positioned to deliver exceptional returns.
CytomX Therapeutics: Innovation in Oncology at Bargain Valuations
Modern cancer therapies face a persistent challenge: collateral damage. While targeting malignant cells, treatments often harm surrounding healthy tissue, reducing efficacy and quality of life. CytomX Therapeutics (NASDAQ: CTMX) addresses this critical gap through its proprietary Probody platform. The technology modifies antibodies to selectively recognize cancerous surfaces, minimizing harm to normal tissue during treatment.
The company’s credibility extends beyond its innovative approach. CTMX has advanced multiple candidates through clinical evaluation, with phase progression anticipated as development continues. Notably, the company maintains partnerships with heavyweight pharmaceutical firms—Regeneron (NASDAQ: REGN) and Bristol-Myers Squibb (NYSE: BMY)—validating its therapeutic approach and accelerating commercialization timelines.
These factors compound to make CTMX particularly attractive for investors seeking cheap stocks with genuine upside. The company trades at levels that belie its technical capabilities and partnership ecosystem. For those willing to take a medium-to-long-term perspective on biotech innovation, CTMX represents an opportunity to build positions before broader market recognition takes hold.
Quhuo: Capturing China’s Evolving Labor Economy
The Chinese economy increasingly depends on flexible labor arrangements—delivery services, household help, transportation coordination. Quhuo (NASDAQ: QH), operating as a flexible workforce solutions provider, positioned itself at the epicenter of this secular trend. The company connects workers with service opportunities across multiple verticals.
The stock experienced prolonged weakness over recent years, eventually stabilizing around historically compressed valuations. Positioned as a Nasdaq-listed ADR, the security operates under specific regulatory requirements. For ADR investors, potential returns depend on asset value appreciation rather than traditional shareholder privileges, a distinction worth understanding.
The underlying business model itself remains compelling. Should Quhuo successfully expand into service-dependent markets like the United States—where labor constraints and on-demand preferences mirror China’s environment—the growth trajectory could reverse significantly. At current pricing, the stock exemplifies the cheap stocks dynamic: legitimate business fundamentals collide with depressed valuations, creating asymmetric opportunity for patient capital.
Lument Finance Trust: Real Estate Income at Accessible Prices
Unlike traditional penny stocks, Lument Finance Trust (NYSE: LFT) operates as a specialized real estate investment trust focused on multifamily housing. Trading near $2.50, it occupies the intersection of affordability and institutional credibility—rare in the cheap stocks universe.
The macro backdrop supports this thesis. Housing increasingly skews toward multifamily configurations as household formation patterns shift and construction costs climb. Families downsize. Urban concentration intensifies. Property costs exceed single-unit economics. These structural trends drive persistent demand for the exact asset class LFT targets. As portfolio values appreciate and rental income flows, shareholders participate in both income distribution and capital appreciation.
For investors seeking steady yield combined with long-term appreciation potential from an ultra-affordable entry point, LFT merits consideration. The combination of low initial cost, established REIT framework, and favorable demographic tailwinds makes it an exceptional vehicle for positioning in housing trends without excessive volatility or complexity.
Understanding Risk in Low-Priced Equity Opportunities
A final critical note: cheap stocks deserve heightened due diligence precisely because lower prices attract speculation. Markets for thinly traded securities can exhibit manipulation. Scam operators exploit information asymmetries in lesser-known stocks. These risks remain real and demand respect.
That said, dismissing all low-priced opportunities as inherently suspect misses legitimate value creation pathways. The companies examined here—CTMX, QH, and LFT—offer concrete business models, transparent financial reporting, and institutional credibility. Each represents a distinct pathway for inexpensive equity exposure to generate meaningful returns, conditional on fundamental thesis realization.
For investors comfortable with holding periods measured in years rather than months, and willing to accept volatility in exchange for growth potential, these three cheap stocks present compelling risk-reward profiles. Position sizing remains paramount; allocating only risk capital you can afford to lose ensures portfolio resilience if outcomes disappoint.